NeuroVive Pharmaceutical AB Kurs / Umsatz
Was ist das Kurs / Umsatz von NeuroVive Pharmaceutical AB?
Kurs / Umsatz von NeuroVive Pharmaceutical AB ist 1,207.19
Was ist die Definition von Kurs / Umsatz?
Das Kurs-Umsatz-Verhältnis ist der Aktienkurs eines Unternehmens im Vergleich zu seinen Einnahmen.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Kurs / Umsatz von Unternehmen in Miscellaneous Sektor auf LSE im Vergleich zu NeuroVive Pharmaceutical AB
Was macht NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Unternehmen mit kurs / umsatz ähnlich NeuroVive Pharmaceutical AB
- CytoDyn hat Kurs / Umsatz von 1,174.39
- Cellular Biomedicine Inc hat Kurs / Umsatz von 1,184.26
- Black Rock Mining hat Kurs / Umsatz von 1,188.66
- Navidea Biopharmaceuticals Inc hat Kurs / Umsatz von 1,194.84
- Kraig Biocraft Laboratories hat Kurs / Umsatz von 1,199.03
- Buderim hat Kurs / Umsatz von 1,206.67
- NeuroVive Pharmaceutical AB hat Kurs / Umsatz von 1,207.19
- Strategic Elements Ltd hat Kurs / Umsatz von 1,216.32
- Greenland Minerals hat Kurs / Umsatz von 1,251.46
- Galantas Gold hat Kurs / Umsatz von 1,271.42
- Kazia Therapeutics hat Kurs / Umsatz von 1,276.66
- Tyranna Resources hat Kurs / Umsatz von 1,282.36
- Leading Leasing Finance And Investment hat Kurs / Umsatz von 1,283.53